Literature DB >> 16284919

Prediction discrepancies for the evaluation of nonlinear mixed-effects models.

France Mentré1, Sylvie Escolano.   

Abstract

Reliable estimation methods for non-linear mixed-effects models are now available and, although these models are increasingly used, only a limited number of statistical developments for their evaluation have been reported. We develop a criterion and a test to evaluate nonlinear mixed-effects models based on the whole predictive distribution. For each observation, we define the prediction discrepancy (pd) as the percentile of the observation in the whole marginal predictive distribution under H(0). We propose to compute prediction discrepancies using Monte Carlo integration which does not require model approximation. If the model is valid, these pd should be uniformly distributed over (0, 1) which can be tested by a Kolmogorov-Smirnov test. In a simulation study based on a standard population pharmacokinetic model, we compare and show the interest of this criterion with respect to the one most frequently used to evaluate nonlinear mixed-effects models: standardized prediction errors (spe) which are evaluated using a first order approximation of the model. Trends in pd can also be evaluated via several plots to check for specific departures from the model.

Mesh:

Year:  2005        PMID: 16284919      PMCID: PMC1989778          DOI: 10.1007/s10928-005-0016-4

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  10 in total

Review 1.  Role of modelling and simulation in Phase I drug development.

Authors:  L Aarons; M O Karlsson; F Mentré; F Rombout; J L Steimer; A van Peer
Journal:  Eur J Pharm Sci       Date:  2001-05       Impact factor: 4.384

Review 2.  Pharmacokinetic/pharmacodynamic modeling in drug development.

Authors:  L B Sheiner; J L Steimer
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

Review 3.  Simulation of clinical trials.

Authors:  N H Holford; H C Kimko; J P Monteleone; C C Peck
Journal:  Annu Rev Pharmacol Toxicol       Date:  2000       Impact factor: 13.820

4.  Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans.

Authors:  L J Lesko; M Rowland; C C Peck; T F Blaschke
Journal:  J Clin Pharmacol       Date:  2000-08       Impact factor: 3.126

5.  Software for population pharmacokinetics and pharmacodynamics.

Authors:  L Aarons
Journal:  Clin Pharmacokinet       Date:  1999-04       Impact factor: 6.447

6.  Population pharmacokinetic analysis of mizolastine and validation from sparse data on patients using the nonparametric maximum likelihood method.

Authors:  F Mesnil; F Mentré; C Dubruc; J P Thénot; A Mallet
Journal:  J Pharmacokinet Biopharm       Date:  1998-04

7.  Estimation of population pharmacokinetics using the Gibbs sampler.

Authors:  N G Best; K K Tan; W R Gilks; D J Spiegelhalter
Journal:  J Pharmacokinet Biopharm       Date:  1995-08

8.  A two-step iterative algorithm for estimation in nonlinear mixed-effect models with an evaluation in population pharmacokinetics.

Authors:  F Mentré; R Gomeni
Journal:  J Biopharm Stat       Date:  1995-07       Impact factor: 1.051

9.  Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Authors:  Y Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

10.  Comparison of the pharmacokinetics of S-1, an oral anticancer agent, in Western and Japanese patients.

Authors:  Emmanuelle Comets; Kazumasa Ikeda; Paulo Hoff; Pierre Fumoleau; Jantien Wanders; Yusuke Tanigawara
Journal:  J Pharmacokinet Pharmacodyn       Date:  2003-08       Impact factor: 2.745

  10 in total
  45 in total

1.  Evaluation of graphical diagnostics for assessing goodness of fit of logistic regression models.

Authors:  Venkata V Pavan Kumar; Stephen B Duffull
Journal:  J Pharmacokinet Pharmacodyn       Date:  2010-12-14       Impact factor: 2.745

2.  Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.

Authors:  Michael N Neely; Michael G van Guilder; Walter M Yamada; Alan Schumitzky; Roger W Jelliffe
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

3.  Population pharmacokinetics of nalmefene in healthy subjects and its relation to μ-opioid receptor occupancy.

Authors:  Lars-Erik Broksoe Kyhl; Shen Li; Kirstine Ullitz Faerch; Birgitte Soegaard; Frank Larsen; Johan Areberg
Journal:  Br J Clin Pharmacol       Date:  2016-01-27       Impact factor: 4.335

4.  A genetic algorithm-based, hybrid machine learning approach to model selection.

Authors:  Robert R Bies; Matthew F Muldoon; Bruce G Pollock; Steven Manuck; Gwenn Smith; Mark E Sale
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-28       Impact factor: 2.745

5.  Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.

Authors:  Karl Brendel; Emmanuelle Comets; Céline Laffont; Christian Laveille; France Mentré
Journal:  Pharm Res       Date:  2006-08-12       Impact factor: 4.200

Review 6.  Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004.

Authors:  Karl Brendel; Céline Dartois; Emmanuelle Comets; Annabelle Lemenuel-Diot; Christian Laveille; Brigitte Tranchand; Pascal Girard; Céline M Laffont; France Mentré
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method.

Authors:  Andrew C Hooker; Christine E Staatz; Mats O Karlsson
Journal:  Pharm Res       Date:  2007-07-06       Impact factor: 4.200

Review 8.  A genetic algorithm based global search strategy for population pharmacokinetic/pharmacodynamic model selection.

Authors:  Mark Sale; Eric A Sherer
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

9.  Valganciclovir Pharmacokinetics in Patients Receiving Oral Prophylaxis Following Kidney Transplantation and Model-Based Predictions of Optimal Dosing Regimens.

Authors:  Thomas Tängdén; Pier Giorgio Cojutti; Jason A Roberts; Federico Pea
Journal:  Clin Pharmacokinet       Date:  2018-11       Impact factor: 6.447

10.  Evaluating renal function and age as predictors of amikacin clearance in neonates: model-based analysis and optimal dosing strategies.

Authors:  Sílvia M Illamola; Helena Colom; J G Coen van Hasselt
Journal:  Br J Clin Pharmacol       Date:  2016-06-30       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.